CTMX
CytomX Therapeutics Inc
2.70$
-0.4%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +169.9% | +1.0% | +99.7% | +15.0% | -25.3% | +5.1% | -5.4% | -23.1% | -22.7% | -40.3% | +25.7% | |
| – | +183.8% | -0.8% | +106.5% | +14.6% | -31.9% | +6.8% | -4.2% | -23.6% | -22.8% | -41.3% | +34.1% | |
| – | -7.1% | +74.9% | +69.7% | +39.4% | -23.9% | +1.8% | +7.1% | -5.8% | -91.1% | +121.6% | -66.7% | |
| – | +189.9% | -2.6% | +105.6% | +16.6% | -32.1% | +6.7% | -3.4% | -36.6% | -9.9% | -42.3% | +36.2% | |
| – | -60.3% | +210.9% | +338.3% | -99.0% | -86.6% | +6,038.5% | -1.0% | +4,455.2% | -90.5% | -9.6% | -35.1% | |
| – | -100.0% | +0.0% | +0.0% | – | – | +0.0% | +0.0% | +0.0% | – | – | – | |
| – | +15.3% | +26.2% | -4.0% | +64.4% | +372.4% | -78.8% | -14.2% | +0.0% | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | +0.0% | +0.0% | -8.3% | -9.1% | -10.0% | -11.1% | -12.5% | -14.3% | -16.7% | -20.0% | -24.9% | |
| – | -53.1% | +69.6% | +171.7% | -0.5% | -11.1% | +26.3% | -31.8% | +38.6% | -28.1% | -51.5% | -56.6% | |
| – | +41.0% | +127.3% | +71.0% | +60.1% | -12.6% | -20.4% | +56.1% | +43.5% | +2.2% | -45.0% | -45.7% | |
| – | – | – | – | – | -78.9% | +13.7% | +13.2% | +12.8% | +12.4% | +12.1% | -17.6% | |
| – | +144.8% | +40.4% | -36.2% | +22.0% | -19.0% | -27.9% | -5.9% | -0.3% | -48.1% | -25.4% | +19.6% | |
| – | -100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | -37.7% | -10.9% | +87.3% | -60.9% | -115.2% | – | -195.9% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.6% | +2.1% | +2.6% | +12.1% | +8.8% | +1.8% | +39.0% | +2.5% | +12.3% | +14.8% | +62.8% |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.